PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.

– Jazz to pay an upfront payment of $200 million to PharmaMar

– Opportunity for Jazz to expand its oncology portfolio with lurbinectedin, a late stage asset in relapsed small cell lung cancer (SCLC)

– PharmaMar is also eligible to receive up to $800 million in potential milestone payments in addition to royalties on net…

Read the full article here

Related Articles